Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2018-11-02 Regulatory Filings
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2018
Regulatory Filings
2018-11-02 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3. It is a correspondence related to a securities registration process, not a financial report or announcement of financial results. The document length is short (1192 characters) and it is a formal regulatory communication. It does not contain financial data, audit information, or report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2018-11-01 English
FORM S-3/A AMENDMENT NO. 2
Capital/Financing Update Classification · 95% confidence The document is a Form S-3/A Amendment No. 2 filed with the SEC, which is a registration statement under the Securities Act of 1933. It is related to the registration of securities for resale by selling stockholders. The text includes detailed information about the securities being registered, the company overview, risk factors, and other prospectus-related content. This type of filing is a capital markets document used for registering securities for public sale, not a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the filing itself, not just an announcement. Hence, the classification is CAP with high confidence.
2018-10-31 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated October 25, 2018, reporting the appointment of a new director, John Landis, Ph.D., to the Board of Directors of EyePoint Pharmaceuticals, Inc. It details the increase in board size, compensation arrangements, and related indemnification agreements. The content focuses on changes in the company's board composition and management. There are no financial statements or earnings data presented, nor is this a report or announcement of financial results. The document fits the category of Board/Management Information (MANG) as it announces changes in the company's board of directors.
2018-10-31 English
10-K/A
Annual Report FY 2018
2018-10-29 English
FORM 4 SUBMISSION
Director's Dealing
2018-10-29 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.